Today brings us more news about companies pursuing opportunities in the biosimilar space. First, we have Merck KGaA saying they plan to invest up to $138 M on biosimilar licensing deals as a means of continuing their growth. These deals will be neccessary to hold revenues and profits steady as their last blockbuster therapy was introduced more than a decade ago, and several high profile programs have failed in late stage clinicals. See Fierce Pharma and First Word Pharma.
Rumors are also rife that Teva is trying to buy Cipla for a third time (a charm?) and has offered $6 B. Cipla has confirmed nothing. Teva is said to be looking to India as a site to lower its manufacturing costs (it announced earlier this week that it would be closng 11 plants worldwide), and that Cipla is also attractive as a producer of biosimilars. Cipla already has produced a biosimilar version of Enbrel and is in the process of going after its version of Humira. Teva wants to become a major player in biosimilars and this may be just the vehicle to use. See Fierce Pharma.
Posted by Bruce Lehr May 9th 2014.